BioPharma / Pharma
Bayer Acquires Perfuse Therapeutics to Enhance Ophthalmology Pipeline
Bayer has acquired Perfuse Therapeutics for $300 million to bolster its ophthalmology pipeline, gaining a mid-stage clinical program for glaucoma and diabetic retinopathy. This acquisition aims to offset declining revenue from its top-selli...